Trinity Biotech plc

Trinity Biotech plc is a commercial-stage biotechnology company specializing in the development, manufacture, and marketing of clinical diagnostic products. Headquartered in Bray, Co. Wicklow, Ireland, the company aims to be a leading player in the international diagnostics industry. It also supplies raw materials to the broader life sciences and research sectors.

The company's extensive product portfolio includes diagnostic tests and instrumentation for a wide range of conditions, such as infectious diseases (e.g., HIV, SARS-CoV-2, syphilis), diabetes monitoring (HbA1c), and various autoimmune disorders like Sjögren's syndrome, celiac disease, and lupus. Trinity Biotech serves both clinical laboratory and point-of-care (POC) segments of the diagnostic market, reaching public health authorities, clinical, and reference laboratories globally. Additionally, the company is actively developing continuous glucose monitoring (CGM) products and wearable biosensors, expanding its focus into diabetes management solutions.

Under the leadership of President and CEO John Gillard, appointed in December 2023, Trinity Biotech is undergoing a comprehensive transformation plan aimed at improving profitability and cash flow. Recent developments include successful clinical results for its enhanced EpiCapture™ Prostate Cancer Test and the rollout of its innovative Premier Hb9210 HbA1c Column System, which received a prestigious "Gold" classification for clinical accuracy. The company is also advancing its CGM+ continuous glucose monitoring system towards pivotal trials in 2026. Despite a recent Nasdaq delisting warning due to not meeting minimum market value requirements, Trinity Biotech secured a $25 million equity financing facility to support its strategic initiatives.